



Health Services
LOS ANGELES COUNTY

**LOS ANGELES COUNTY DEPARTMENT OF HEALTH SERVICES
CORE PHARMACY & THERAPEUTICS COMMITTEE**

January 2022

TO: MHLA Clinics

FROM: Joseph Allevato, M.D.
Jean Pallares, Pharm.D.
Chairs, DHS Core Pharmacy and Therapeutics Committee

RE: DHS MHLA Formulary Update

MY HEALTH LA FORMULARY

Formulary Addition

Drug Product	Comments
Naloxone 4mg/0.1ml Nasal Spray	MAT Quantity limited to one claim per year (two ready-to-use devices). Generic only. Outpatient use: no clinical restrictions. Potential patients for use include: High risk for over dose (>100 Morphine Equivalents per day); OR Concern for concurrent use with illicit substances or high risk Rx Meds (e.g. BZD); OR Comorbidities (e.g. morbid obesity, obstructive sleep apnea), high risk for intentional/accidental overdose (e.g. depression, suicidal thoughts, limited literacy), high risk household (e.g. children or other addicts present) Effective 01/21/2022

Formulary Restriction Update

Drug Product	Comments
Naloxone 0.4mg/ml injectable	MAT Quantity limited to one claim per year (two vials). Outpatient use: no clinical restrictions. Potential patients for use include: High risk for over dose (>100 Morphine Equivalents per day); OR Concern for concurrent use with illicit substances or high risk Rx Meds (e.g. BZD); OR Comorbidities (e.g. morbid obesity, obstructive sleep apnea), high risk for intentional/accidental overdose (e.g. depression, suicidal thoughts, limited literacy), high risk household (e.g. children or other addicts present) Effective 01/21/2022

This document contains confidential information intended for Los Angeles County Health Professionals and employees only. Unintended recipients may not disclose, copy, distribute, or take any action based on this document. This information is not to be disclosed to pharmaceutical representatives, press, or other outside agents.